Not Yet Recruiting
Evaluation of the Efficacy of Darolutamide Triplet Therapy in Patients With Metastatic Hormone-sensitive Prostate Cancer
NCT07031258
- Conditions
- Darolutamide (DARO) in Combination With Androgen-deprivation Therapy (ADT) and Docetaxel (DOC), Metastatic Hormone-sensitive Prostate Cancer
- Locations
-
Not specified